David Schaffer is the Hubbard Howe Professor of Chemical and Biomolecular Engineering, Bioengineering, and Molecular and Cell Biology at the University of California, Berkeley, and he also serves as Director of QB3 and Bakar Labs. He completed his B.S. in chemical engineering at Stanford University in 1993, his Ph.D. in chemical engineering at MIT in 1998, and a postdoctoral fellowship at the Salk Institute for Biological Studies in 1999 before joining Berkeley in 1999. There, he applies engineering principles to optimize gene and stem cell therapies, work that includes developing the concept of applying directed evolution to engineer targeted and efficient viral gene therapy vectors as well as new technologies to investigate and control stem cell function. He has published >250 papers, has advised >90 graduate students and postdoctoral fellows, is an inventor on >50 issued patents, and developed technologies that are being used in 10 human clinical trials. In addition, he has co-founded eight companies, including 4D Molecular Therapeutics (NASDAQ FDMT), Ignite Immunotherapies (acquired by Pfizer) and Rewrite (acquired by Intellia). Finally, he has received recognitions including the National Academy of Engineering, National Academy of Inventors, Andreas Acrivos Professional Progress Award, the American Institute of Chemical Engineers Pharmaceutical and Bioengineering Award, the American Chemical Society Marvin Johnson Award, the Biomedical Engineering Society Rita Shaffer Young Investigator Award, and others.